uniQure N.V. Costs and Expenses
uniQure N.V. (QURE) reported Costs and Expenses of $49.46 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-05-05
- uniQure N.V. costs and expenses for the quarter ending 2026-03-31 was $49.46M, a 4.69% increase year-over-year.
- uniQure N.V. costs and expenses for the quarter ending 2025-12-31 was $56.83M, a 11.79% increase year-over-year.
- uniQure N.V. costs and expenses for the quarter ending 2025-09-30 was $54.20M, a 25.49% increase year-over-year.
- uniQure N.V. costs and expenses for the quarter ending 2025-06-30 was $49.54M, a 12.91% decline year-over-year.
- uniQure N.V. costs and expenses for fiscal 2025 was $207.81M, a 3.24% decline from fiscal 2024.
- uniQure N.V. costs and expenses for fiscal 2024 was $214.77M, a 29.14% decline from fiscal 2023.
- uniQure N.V. costs and expenses for fiscal 2023 was $303.08M, a 18.40% increase from fiscal 2022.
- uniQure N.V. costs and expenses for fiscal 2022 was $255.99M, a 13.87% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-03-31 | $49.46M 10-Q · filed 2026-05-05 | $106.29M derived: sum of 2 quarters · filed 2026-05-05 | $160.49M derived: sum of 3 quarters · filed 2026-05-05 | $210.03M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $56.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $111.03M derived: sum of 2 quarters · filed 2026-03-02 | $160.57M derived: sum of 3 quarters · filed 2026-03-02 | $207.81M 10-K · filed 2026-03-02 |
| 2025-09-30 | $54.20M 10-Q · filed 2025-11-10 | $103.74M derived: sum of 2 quarters · filed 2025-11-10 | $150.99M 10-Q · filed 2025-11-10 | $201.82M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $49.54M 10-Q · filed 2025-07-29 | $96.78M 10-Q · filed 2025-07-29 | $147.62M derived: sum of 3 quarters · filed 2026-05-05 | $190.81M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $47.24M 10-Q · filed 2026-05-05 | $98.08M derived: sum of 2 quarters · filed 2026-05-05 | $141.27M derived: sum of 3 quarters · filed 2026-05-05 | $198.16M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $50.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $94.03M derived: sum of 2 quarters · filed 2026-03-02 | $150.91M derived: sum of 3 quarters · filed 2026-03-02 | $214.77M 10-K · filed 2026-03-02 |
| 2024-09-30 | $43.19M 10-Q · filed 2025-11-10 | $100.07M derived: sum of 2 quarters · filed 2025-11-10 | $163.93M 10-Q · filed 2025-11-10 | $232.87M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $56.88M 10-Q · filed 2025-07-29 | $120.74M 10-Q · filed 2025-07-29 | $189.68M derived: sum of 3 quarters · filed 2026-03-02 | $274.16M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $63.85M 10-Q · filed 2025-05-09 | $132.80M derived: sum of 2 quarters · filed 2026-03-02 | $217.28M derived: sum of 3 quarters · filed 2026-03-02 | $285.85M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $68.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $153.42M derived: sum of 2 quarters · filed 2026-03-02 | $221.99M derived: sum of 3 quarters · filed 2026-03-02 | $303.08M 10-K · filed 2026-03-02 |
| 2023-09-30 | $84.48M 10-Q · filed 2024-11-05 | $153.05M derived: sum of 2 quarters · filed 2024-11-05 | $234.14M 10-Q · filed 2024-11-05 | $312.38M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $68.57M 10-Q · filed 2024-08-01 | $149.66M 10-Q · filed 2024-08-01 | $227.90M derived: sum of 3 quarters · filed 2025-02-27 | $290.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $81.09M 10-Q · filed 2024-05-07 | $159.33M derived: sum of 2 quarters · filed 2025-02-27 | $221.58M derived: sum of 3 quarters · filed 2025-02-27 | $281.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $78.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $140.49M derived: sum of 2 quarters · filed 2025-02-27 | $200.00M derived: sum of 3 quarters · filed 2025-02-27 | $255.99M 10-K · filed 2025-02-27 |
| 2022-09-30 | $62.25M 10-Q · filed 2023-11-07 | $121.77M derived: sum of 2 quarters · filed 2023-11-07 | $177.76M 10-Q · filed 2023-11-07 | $235.86M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $59.52M 10-Q · filed 2023-08-01 | $115.50M 10-Q · filed 2023-08-01 | $173.61M derived: sum of 3 quarters · filed 2024-02-28 | $222.06M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $55.99M 10-Q · filed 2023-05-09 | $114.09M derived: sum of 2 quarters · filed 2024-02-28 | $162.55M derived: sum of 3 quarters · filed 2024-02-28 | $235.77M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $58.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $106.56M derived: sum of 2 quarters · filed 2024-02-28 | $179.78M derived: sum of 3 quarters · filed 2024-02-28 | $224.81M 10-K · filed 2024-02-28 |
| 2021-09-30 | $48.45M 10-Q · filed 2022-11-02 | $121.68M derived: sum of 2 quarters · filed 2022-11-02 | $166.71M 10-Q · filed 2022-11-02 | $209.60M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $73.22M 10-Q · filed 2022-08-08 | $118.25M 10-Q · filed 2022-08-08 | $161.15M derived: sum of 3 quarters · filed 2023-02-27 | $208.24M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $45.03M 10-Q · filed 2022-05-02 | $87.92M derived: sum of 2 quarters · filed 2023-02-27 | $135.01M derived: sum of 3 quarters · filed 2023-02-27 | $174.93M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $42.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $89.98M derived: sum of 2 quarters · filed 2023-02-27 | $129.90M derived: sum of 3 quarters · filed 2023-02-27 | $164.98M 10-K · filed 2023-02-27 |
| 2020-09-30 | $47.09M 10-Q · filed 2021-10-25 | $87.00M derived: sum of 2 quarters · filed 2021-10-25 | $122.09M 10-Q · filed 2021-10-25 | $157.26M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $39.91M 10-Q · filed 2021-07-26 | $75.00M 10-Q · filed 2021-07-26 | $110.17M derived: sum of 3 quarters · filed 2022-02-25 | $142.65M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $35.09M 10-Q · filed 2021-05-10 | $70.25M derived: sum of 2 quarters · filed 2022-02-25 | $102.74M derived: sum of 3 quarters · filed 2022-02-25 | $134.76M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $35.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $67.65M derived: sum of 2 quarters · filed 2022-02-25 | $99.68M derived: sum of 3 quarters · filed 2022-02-25 | $128.28M 10-K · filed 2022-02-25 |
| 2019-09-30 | $32.48M 10-Q · filed 2020-10-27 | $64.51M derived: sum of 2 quarters · filed 2020-10-27 | $93.11M 10-Q · filed 2020-10-27 | $119.04M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $32.02M 10-Q · filed 2020-07-30 | $60.63M 10-Q · filed 2020-07-30 | $86.56M derived: sum of 3 quarters · filed 2021-03-01 | $112.99M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $28.60M 10-Q · filed 2020-04-29 | $54.53M derived: sum of 2 quarters · filed 2021-03-01 | $80.97M derived: sum of 3 quarters · filed 2021-03-01 | $105.36M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $25.93M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $52.37M derived: sum of 2 quarters · filed 2021-03-01 | $76.75M derived: sum of 3 quarters · filed 2021-03-01 | $100.11M 10-K · filed 2021-03-01 |
| 2018-09-30 | $26.44M 10-Q · filed 2019-10-28 | $50.83M derived: sum of 2 quarters · filed 2019-10-28 | $74.19M 10-Q · filed 2019-10-28 | |
| 2018-06-30 | $24.39M 10-Q · filed 2019-07-29 | $47.75M 10-Q · filed 2019-07-29 | ||
| 2017-12-31 | $96.81M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |